Atrix has begun manufacturing launch quantities of its periodontal disease treatment Atridox, Atrix Vice Chairman and CEO John Urheim indicates. "Coming Soon" ads, placed by marketing partner Block Drug, are now appearing in dental journals. Block will promote the doxycyline gel with 80 sales reps. The marketing agreement includes $50 mil. in milestone payments and $10 mil. at approval. FDA issued an "approvable" letter April 8; Atrix is discussing labeling with the agency
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth